REM-0045392(REM-0045392) - 在研适应症：阿尔茨海默症_专利_临床

概要

基本信息

药物类型

未知

别名

REM-0045392

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病

在研适应症

阿尔茨海默症

非在研适应症-

原研机构

reMYND NV

在研机构

reMYND NV

非在研机构-

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

1

项与 REM-0045392 相关的临床试验

NCT07016464

/ Active, not recruiting临床1期

A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of REM0045392 to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Food Effect in Healthy Male Participants and in a Panel of Healthy Elderly Participants (Both Sexes)

This study is testing if the medicine REM0045392 is safe and well-tolerated. It also looks at whether food affects how the medicine works.
The medicine will be tested in Healthy men (Part 1 and 2) and Healthy Older men and women (Part 3).
Participants will take the medicine once (in Part 1) or during 10 days (in Part 2 and 3), with increasing doses.
REM0045392 is being developed as a treatment for Alzheimer's disease.

开始日期2025-03-20

申办/合作机构

reMYND NV

100 项与 REM-0045392 相关的临床结果

登录后查看更多信息

100 项与 REM-0045392 相关的转化医学

登录后查看更多信息

100 项与 REM-0045392 相关的专利（医药）

登录后查看更多信息

100 项与 REM-0045392 相关的药物交易

登录后查看更多信息